AzTrials
AzTrials

Percutaneous NephrolithotomyNCT05947435

Tranexamic Acid in Percutaneous Nephrolithotomy

A study testing Tranexamic acid in people with Percutaneous Nephrolithotomy and Intraoperative Use of Tranexamic Acid, run by Haseki Training and Research Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Tranexamic acid, once a randomly used antifibrinolytic agent, has been in standard protocols for many specific surgeries. Studies are still needed to standardize the dose and route of tranexamic acid administration, examine its possible contributions in urological surgery, and establish a protocol for its use. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
Tranexamic acid
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jan 2022to 1 Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18-70 years old
  • ASA I-III patients
  • scheduled for PCNL surgery

Who cannot join

  • tranexamic acid hypersensitivity
  • history of subarachnoid haemorrhage
  • previous cerebrovascular event
  • a history of arterial-venous embolism or a tendency to thromboembolism
  • abnormal liver function tests
  • unstable cardiovascular disease
  • acute or chronic renal failure
  • the presence of any haematological disease and known colour blindness

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Haseki Training and Research Hospital

    Istanbul, Sultangazi, 34000

Other trials in Turkey (Türkiye)

About this study

Official title: The Effect of Use of Tranexamic Acid in Percutaneous Nephrolithotomy on Blood Loss and Surgical Visual Clarity

Tranexamic acid, once a randomly used antifibrinolytic agent, has been in standard protocols for many specific surgeries. Studies are still needed to standardize the dose and route of tranexamic acid administration, examine its possible contributions in urological surgery, and establish a protocol for its use.

To contribute to this goal, the study was designed as a prospective, randomized, double-blind study on 75 patients with one control and 2 study groups (n=25) who underwent percutaneous nephrolithotomy. Group Tranexamic acid received 10 mg/kg intravenous tranexamic acid preoperatively. And Group Irrigation received the same amount in the initial irrigation fluid. Primarily,the total amount of blood transfusion and the changes in haemoglobin and haematocrit values during two postoperative days were observed. Distinctively, continuous intraoperative haemoglobin saturation was monitored. Secondarily, surgical visual clarity with a standard visual score was questioned to reveal its contribution to surgical practicality, operative time, and residual fragment quantity.

Read the detailed description

The study was designed as a double-blind, prospective, randomised, controlled study after approval of our Institutional ethics committee (dossier no: 108-2021) and assessed patients scheduled for PCNL after January 2022 for eligibility. After obtaining written informed consent, 75 patients (3 groups; 1:1:1 distribution; n=25) were allocated, and the study was conducted in Haseki Training and Research Hospital until May 2023, with the principles outlined in the Helsinki Declaration.

Study subjects The study population was 18-70 years old and ASA I-III patients scheduled for PCNL surgery. Exclusion criteria were tranexamic acid hypersensitivity, history of subarachnoid haemorrhage, previous cerebrovascular event, a history of arterial-venous embolism or a tendency to thromboembolism, abnormal liver function tests, unstable cardiovascular disease, acute or chronic renal failure, presence of any haematological disease and known colour blindness.

Patient randomization and blindness Randomization was designed as 3 (n= 25) named Groups A, B, and Group C in a 1:1:1 ratio with a computer-based algorithm and sealed in opaque envelopes by the surgeon assigned to the study. The investigative anesthesiologist selected an envelope in the order of numbers on it, and Group A continued with an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision. In Group B, 10 mg/kg tranexamic acid was placed in the first irrigation solution; in Group C, no drug was given either way. The urologist was blind to the study groups and was the evaluator of an intraoperative visual score. Postoperative Hb and Hct values and complications were followed by the surgeons who were also blinded to the groups, and the decision of blood replacement was made according to the Hct values according to our standard protocol of the urology department.

Anaesthesia and surgical technique All surgeries were performed under general anaesthesia with standard monitorisation and non-invasive MASIMO Hemoglobin (SpHb®) real-time monitoring. After the ureteral catheter was placed, the patient was placed in a prone position. After sequential dilatations were performed under fluoroscopy, a 16.5 Fr or 21 Fr am Platz sheath was placed in the pelvicalyceal system. Ho: YAG Laser lithotripter (Sphinx, Lisa laser, USA) was used to fragment stones. According to the surgeon's decision, a JJ stent and/or a nephrostomy tube were placed at the final of the operation.

Primary outcome The primary outcome was the comparison of changes in haemoglobin and haematocrit values during two postoperative days with changes in intraoperative SpHb values and postoperative need for blood transfusion. SpHb was monitored throughout the surgery; however, the value of change before and immediately after surgery was a major concern. Blood samples were evaluated for Hb and Hct values on the first night and the second morning after surgery. Indications for blood transfusion were below 30% hematocrit level.

Secondary outcomes The effect on surgical outcomes was questioned by residual fragment (%) and postoperative complications. The effect on surgical practice was evaluated by operation time (minute) and visual score of the surgeon. At the end of the surgery, the assigned surgeon who was blind to the groups was asked to rate the visual clarity by a score pre-designed for arthroscopic surgeries as 'Bad-Medium, Good or Perfect'. A visual scoring from 1 to 10 was used, with 10 for the perfect image, 4-10 as good and 1-4 as bad-medium. We searched for bleeding, angioembolisation, infection, reoperation, and thrombotic complications, especially pulmonary emboli.

Statistical analysis and sample size calculation The mean sample size was calculated using the G Power 3.1 analysis program. The sample size was estimated at 90% power and 8% significance level, and it was determined that at least 20 patients per group were required to obtain a statistically significant value. Therefore, we included 25 patients in each group to prevent possible dropouts.

The Statistical Package for the Social Sciences version 27 (SPSS IBM Corp., Armonk, NY, USA) program was used. The normality of the distribution of the variables was checked by the Shapiro-Wilk test and Q-Q plots. The one-way ANOVA test or Kruskal-Wallis test was used for the comparison of continuous variables. Comparison between groups was performed with Tukey posthoc analysis. Qualitative data are shown as mean ± standard deviation or median (IQR). Quantitative data are shown as mean ± standard deviation values. The data were analyzed at a 95% confidence level.

Being tested
Tranexamic acid
Keywords
blood loss, percutaneous nephrolithotomy, tranexamic acid, visual image quality
Medical subject headings
Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tranexamic acidDrug

    Also called Transamin®

    Tranexamic acid was administered in intravenous or locally within irrigation fluid

Study groups in NCT05947435
Study groupRoleWhat they receive
Tranexamic acid IVExperimentalGroup A received an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision.
Receives: Drug: Tranexamic acid
Tranexamic acid irrigationExperimental10 mg/kg tranexamic acid was placed in the first irrigation solution
Receives: Drug: Tranexamic acid
ControlNo interventionThe control group did not receive tranexamic acid in either way

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hemoglobin decrease

    Hemoglobin decrease after postoperative first and second day relevant to preoperative values

    Measured: postoperative 48 hours

  2. Blood product requirement

    number of packed red blood cell use

    Measured: postoperative 48 hours

Secondary outcomes (1)
  1. surgical visual score

    A visual scoring from 1 to 10 was used, with 10 for the perfect image, 4-10 as good and 1-4 as bad-medium

    Measured: intraoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2023
  2. Study start1 Jan 2022
  3. Primary completion1 May 2023
  4. Study completion1 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05947435
Sponsor's protocol ID
108-2021
Status last verified
Jul 2023
First submitted
7 Jul 2023
Last updated
19 Jul 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Ersin M, Demirel M, Buget MI, Edipoglu IS, Atalar AC, Ersen A. The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study. Acta Orthop Traumatol Turc. 2020 Nov;54(6):572-576. doi: 10.5152/j.aott.2020.19164.

    PubMed 33423986
  • Kim J, Alrumaih A, Donnelly C, Uy M, Hoogenes J, Matsumoto ED. The impact of tranexamic acid on perioperative outcomes in urological surgeries A systematic review and meta-analysis. Can Urol Assoc J. 2023 Jun;17(6):205-216. doi: 10.5489/cuaj.8254.

    PubMed 36952300

Questions about this trial

What is this clinical trial studying?

A study testing Tranexamic acid in people with Percutaneous Nephrolithotomy and Intraoperative Use of Tranexamic Acid, run by Haseki Training and Research Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hemoglobin decrease (time frame: postoperative 48 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05947435, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in